# The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting

> **NCT03278262** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2312 (actual)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT03278262
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2017-12-31
- **Final completion:** 2017-12-31
- **Target enrollment:** 2312 (ACTUAL)
- **Last updated:** 2018-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278262, "The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03278262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*